LuxIA receives CE-MDR certification

News
Article

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

Image credit: AdobeStock/Shuo

(Image credit: AdobeStock/Shuo)

RetinAI US Inc. and Fundación Ver Salud issued a joint press release1 that LuxIA, the co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has received CE-MDR certification as a Class IIb medical device under the European Union Medical Device Regulation (EU MDR 2017/745). The certification was granted through Ikerian AG, RetinAI’s parent company.

The program, LuxIA, is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy (mtmDR). The companies shared that this new certification shows their commitment to deliver AI-driven tools that meet stringent regulatory standards and significantly enhance patient management and clinical outcomes.

Dr. Carlos Ciller, CEO and co-founder of RetinAI, commented on this certification and the future of LuxIA in the joint press release,1 saying, “Receiving CE-MDR certification for LuxIA underscores our shared commitment with FVS to advance leading-edge ophthalmic care to patients through reliable and impactful AI technology. This milestone is pivotal, enabling healthcare providers to improve patient management and outcomes for diabetic retinopathy across Europe, reinforcing our joint mission of transforming vision care through innovation.”

Dr. Juan Donate, MD, President of Fundación Ver Salud also shared his thorugh on the certification, saying, “We are excited about the newly received certification and look forward to the significant impact LuxIA will have in the European ophthalmology market. AI-driven screening solutions are critical to improving patient care, and we anticipate LuxIA will play a central role in achieving this.”1

The device is indicated for processing digital 45-degree colour fundus images from NW200, NW400 or equivalent Topcon cameras. Together with RetinAI’s existing portfolio of AI-based OCT analysis solutions, LuxIA complements a comprehensive suite of clinically validated, CE-certified AI modules focused on ophthalmology.1

Reference:
1. RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®. RetinAI US Inc. April 30, 2025. Accessed April 30, 2025. https://www.morningstar.com/news/globe-newswire/1001093193/retinai-and-fvs-announce-ce-mdr-certification-for-co-developed-ai-based-diabetic-retinopathy-screening-algorithm-luxia

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.